Further description found that patients with anti-MDA5 have a unique clinical phenotype that includes CADM or classical dermatomyositis (DM), rapid progressive interstitial lung disease (RP-ILD), arthritis, and vasculopathy lesions [3, 4]. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.